Alitretinoin
This article is licensed under the GNU Free Documentation License. It uses material from the Wikipedia article "Alitretinoin".

Alitretinoin
Systematic (IUPAC) name
(2E,4E,6Z,8E)-3,7-dimethyl-9-(2,6,6-trimethyl- 1-cyclohexenyl)nona-2,4,6,8-tetraenoic acid
Identifiers
CAS number	5300-03-8
ATC code	L01XX22
PubChem	449171
DrugBank	APRD00017
Chemical data
Formula	C20H28O2
Mol. mass	300.435 g/mol
Pharmacokinetic data
Bioavailability	?
Metabolism	?
Half life	?
Excretion	?
Therapeutic considerations
Pregnancy cat.	?
Legal status	Rx only
Routes	Topical

Alitretinoin (tradename Panretin) is an antineoplastic agent developed by Ligand Pharmaceuticals.

It is a first generation retinoid.

Clinical uses

Alitretinoin is indicated for the topical treatment of cutaneous lesions in patients with AIDS-related Kaposi’s sarcoma. It is not indicated when systemic anti-KS therapy is required (e.g., more than 10 new KS lesions in the prior month, symptomatic lymphedema, symptomatic pulmonary KS, or symptomatic visceral involvement). There is no experience to date using alitretinoin with systemic anti-KS treatment.

History

Ligand gained Food and Drug Administration (FDA) approval for alitretinoin in February 1999.

External links

• Prescribing Information (revised February 2007). Retrieved on 01-30-08.